Related Experiment Video

Updated: Apr 3, 2026

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
09:04

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

Published on: March 15, 2016

10.3K

Exploring the Molecular Interactions of 7,8-Dihydroxyflavone and Its Derivatives with TrkB and VEGFR2 Proteins

Nitin Chitranshi1, Vivek Gupta2, Sanjay Kumar3

  • 1Faculty of Medicine and Health Sciences, Macquarie University, F10A, 2 Technology Place, North Ryde, NSW 2109, Australia. nitin.chitranshi@students.mq.edu.au.

International Journal of Molecular Sciences
|September 26, 2015
PubMed

Insights

7,8-dihydroxyflavone (7,8-DHF) activates TrkB receptors but inhibits VEGFR2 phosphorylation. This flavonoid derivative shows dual action, impacting both neurotrophic signaling and vascular pathways, with potential implications for retinal health.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Neuroscience

Background:

  • 7,8-dihydroxyflavone (7,8-DHF) is a TrkB receptor agonist, enhancing downstream signaling.
  • Flavonoids can inhibit vascular endothelial growth factor receptors (VEGFRs), including VEGFR2, which is crucial for angiogenesis and has neuroprotective roles.
  • VEGFR2 dysregulation is linked to conditions like age-related macular degeneration.

Purpose of the Study:

  • To investigate the molecular interactions of 7,8-DHF and its derivatives with both TrkB and VEGFR2.
  • To elucidate binding energies and key residues involved in these interactions.
  • To understand the dual biochemical action of 7,8-DHF on these receptors.

Main Methods:

  • Molecular docking simulations.
  • Computational mapping using molecular dynamics.
  • In vitro assays using 661W photoreceptor cells and retinal tissue.

Main Results:

  • 7,8-DHF interacts with the TrkB Ig2 domain and the intracellular kinase domain of VEGFR2.
  • The study identified specific residues and binding energies for these interactions.
  • 7,8-DHF downregulates VEGFR2 phosphorylation, contrasting its agonistic effect on TrkB.

Conclusions:

  • 7,8-DHF exhibits dual biochemical activity, acting as a TrkB agonist and a VEGFR2 inhibitor.
  • This dual action suggests potential divergent therapeutic effects on neurotrophic and vascular pathways.
  • Findings provide novel insights into the molecular mechanisms of 7,8-DHF in retinal cells and tissue.
Keywords:
7,8-DHFBDNFTrkB receptorVEGFR2 receptordockingglaucomamolecular dynamicsneurodegenerative disorderretina

More Related Videos

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B11:44

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

3.1K
Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.9K

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
4.0K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
8.3K
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
89.0K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
20.8K
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
514